Clinical Trial Update: A Safety Study of SGN-CD19A for B-Cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 safety study of SGN-CD19A in various B-cell lymphomas has completed; the update summarizes safety results across multiple indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Precursor B-cell Lymphoblastic Leukemia Lymphoma

Drugs mentioned

• SGN-CD19A

Snippet

Sponsor: Seagen Inc. | Conditions: Burkitt Lymphoma, Lymphoma, Follicular | Phase 1 | Status: COMPLETED